Cargando…
Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion
BACKGROUND: Atrial fibrillation (AF) cycle length (CL) and atrial size have been used in humans to characterize electrical and structural remodeling to predict outcome of cardioversion of AF and risk for AF recurrence (rAF). HYPOTHESIS: Atrial fibrillation cycle length can be determined in horses wi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858013/ https://www.ncbi.nlm.nih.gov/pubmed/24611990 http://dx.doi.org/10.1111/jvim.12322 |
_version_ | 1782430732731285504 |
---|---|
author | De Clercq, D. Decloedt, A. Sys, S.U. Verheyen, T. Van Der Vekens, N. van Loon, G. |
author_facet | De Clercq, D. Decloedt, A. Sys, S.U. Verheyen, T. Van Der Vekens, N. van Loon, G. |
author_sort | De Clercq, D. |
collection | PubMed |
description | BACKGROUND: Atrial fibrillation (AF) cycle length (CL) and atrial size have been used in humans to characterize electrical and structural remodeling to predict outcome of cardioversion of AF and risk for AF recurrence (rAF). HYPOTHESIS: Atrial fibrillation cycle length can be determined in horses with AF, and AFCL and atrial size are related to risk for rAF. ANIMALS: Eighteen horses with naturally occurring AF that were successfully converted to sinus rhythm (SR) by transvenous electrical cardioversion (TVEC). METHODS: Prospective study. Horses with severe valvular regurgitation, left atrial enlargement, or that required sedation for catheter placement were excluded. In all horses intra‐atrial electrograms were recorded and estimated AF duration and echocardiographic parameters were determined before TVEC. The follow‐up time was 1 year after TVEC. RESULTS: Atrial fibrillation cycle length could be determined in all horses. The AFCL and the shortest 5th percentile (p5) AFCL in horses with rAF (n = 6 or 33%) were (mean ± SD) 157 ± 28 and 134 ± 24 milliseconds, respectively, and in those maintaining SR (n = 12 or 67%) 166 ± 13 and 141 ± 13 milliseconds, respectively. Significant parameters to predict rAF were (1) the ratios of the p5AFCL to the left atrium (LA) sizes corrected to the size of aorta (AO) and (2) LA sizes corrected to the size of AO. CONCLUSIONS AND CLINICAL IMPORTANCE: Before TVEC, assessment of LA size and atrial electrophysiologic characteristics might help to identify horses at increased risk for AF recurrence. |
format | Online Article Text |
id | pubmed-4858013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48580132016-06-22 Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion De Clercq, D. Decloedt, A. Sys, S.U. Verheyen, T. Van Der Vekens, N. van Loon, G. J Vet Intern Med Standard Articles BACKGROUND: Atrial fibrillation (AF) cycle length (CL) and atrial size have been used in humans to characterize electrical and structural remodeling to predict outcome of cardioversion of AF and risk for AF recurrence (rAF). HYPOTHESIS: Atrial fibrillation cycle length can be determined in horses with AF, and AFCL and atrial size are related to risk for rAF. ANIMALS: Eighteen horses with naturally occurring AF that were successfully converted to sinus rhythm (SR) by transvenous electrical cardioversion (TVEC). METHODS: Prospective study. Horses with severe valvular regurgitation, left atrial enlargement, or that required sedation for catheter placement were excluded. In all horses intra‐atrial electrograms were recorded and estimated AF duration and echocardiographic parameters were determined before TVEC. The follow‐up time was 1 year after TVEC. RESULTS: Atrial fibrillation cycle length could be determined in all horses. The AFCL and the shortest 5th percentile (p5) AFCL in horses with rAF (n = 6 or 33%) were (mean ± SD) 157 ± 28 and 134 ± 24 milliseconds, respectively, and in those maintaining SR (n = 12 or 67%) 166 ± 13 and 141 ± 13 milliseconds, respectively. Significant parameters to predict rAF were (1) the ratios of the p5AFCL to the left atrium (LA) sizes corrected to the size of aorta (AO) and (2) LA sizes corrected to the size of AO. CONCLUSIONS AND CLINICAL IMPORTANCE: Before TVEC, assessment of LA size and atrial electrophysiologic characteristics might help to identify horses at increased risk for AF recurrence. John Wiley and Sons Inc. 2014-02-24 2014 /pmc/articles/PMC4858013/ /pubmed/24611990 http://dx.doi.org/10.1111/jvim.12322 Text en Copyright © 2014 by the American College of Veterinary Internal Medicine |
spellingShingle | Standard Articles De Clercq, D. Decloedt, A. Sys, S.U. Verheyen, T. Van Der Vekens, N. van Loon, G. Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion |
title | Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion |
title_full | Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion |
title_fullStr | Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion |
title_full_unstemmed | Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion |
title_short | Atrial Fibrillation Cycle Length and Atrial Size in Horses with and without Recurrence of Atrial Fibrillation after Electrical Cardioversion |
title_sort | atrial fibrillation cycle length and atrial size in horses with and without recurrence of atrial fibrillation after electrical cardioversion |
topic | Standard Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858013/ https://www.ncbi.nlm.nih.gov/pubmed/24611990 http://dx.doi.org/10.1111/jvim.12322 |
work_keys_str_mv | AT declercqd atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion AT decloedta atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion AT syssu atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion AT verheyent atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion AT vandervekensn atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion AT vanloong atrialfibrillationcyclelengthandatrialsizeinhorseswithandwithoutrecurrenceofatrialfibrillationafterelectricalcardioversion |